Bayer eliminates nearly half of its executive positions in major overhaul
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes.
If you are not happy with the results below please do another search
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes.
The company stated that a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.
A new analysis from the Congressional Budget Office predicts that Novo Nordisk’s semaglutide will likely be subjected to Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.
Bayer predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker’s growth prospects after the failure of a promising anti-blood-clotting therapy.
The partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversations.
The 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device.
Large volumes of diabetes drug Ozempic are not being exported from Germany, its health ministry said, quashing a suggestion by its drugs regulator that outbound trade in the drug, coveted for its weight-loss effect, may have to be banned.
The site, designed to produce large-scale biologics for Roche’s Genentech, will help Lonza meet the demand for commercial mammalian products from other companies and make molecules in development
The deal involves a partnership to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.